Sharon Beth Brodie Wright, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infection Control | 10 | 2023 | 985 | 1.580 |
Why?
|
| Cross Infection | 12 | 2023 | 1426 | 1.550 |
Why?
|
| Staphylococcal Infections | 6 | 2019 | 1398 | 1.040 |
Why?
|
| Equipment Contamination | 5 | 2019 | 183 | 1.020 |
Why?
|
| Mastitis | 2 | 2013 | 43 | 0.820 |
Why?
|
| Vancomycin | 5 | 2019 | 505 | 0.690 |
Why?
|
| Norovirus | 1 | 2020 | 37 | 0.680 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2019 | 703 | 0.680 |
Why?
|
| Abscess | 2 | 2013 | 606 | 0.630 |
Why?
|
| Gastroenteritis | 1 | 2020 | 236 | 0.600 |
Why?
|
| Staphylococcus aureus | 4 | 2019 | 1429 | 0.590 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2019 | 342 | 0.590 |
Why?
|
| Influenza Vaccines | 2 | 2019 | 780 | 0.580 |
Why?
|
| Duodenoscopes | 4 | 2019 | 43 | 0.570 |
Why?
|
| Microbiological Techniques | 2 | 2017 | 97 | 0.550 |
Why?
|
| Candida | 1 | 2017 | 172 | 0.510 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 1545 | 0.480 |
Why?
|
| Candidiasis | 1 | 2017 | 367 | 0.450 |
Why?
|
| Drug Utilization Review | 2 | 2005 | 248 | 0.450 |
Why?
|
| Influenza, Human | 2 | 2019 | 1539 | 0.440 |
Why?
|
| Disease Outbreaks | 4 | 2022 | 1762 | 0.420 |
Why?
|
| Guideline Adherence | 3 | 2018 | 2240 | 0.330 |
Why?
|
| Spine | 1 | 2016 | 1141 | 0.330 |
Why?
|
| Postpartum Period | 2 | 2013 | 1197 | 0.320 |
Why?
|
| Academic Medical Centers | 6 | 2020 | 2783 | 0.320 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2009 | 78 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 7 | 2018 | 7463 | 0.300 |
Why?
|
| Disinfection | 3 | 2019 | 207 | 0.290 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2010 | 262 | 0.290 |
Why?
|
| Soft Tissue Infections | 1 | 2009 | 168 | 0.280 |
Why?
|
| Antiviral Agents | 1 | 2019 | 3064 | 0.270 |
Why?
|
| Carrier State | 2 | 2011 | 529 | 0.270 |
Why?
|
| Equipment Reuse | 4 | 2022 | 45 | 0.270 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2015 | 278 | 0.260 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2009 | 1196 | 0.240 |
Why?
|
| Communicable Diseases | 3 | 2024 | 873 | 0.240 |
Why?
|
| Catheterization, Central Venous | 2 | 2015 | 536 | 0.240 |
Why?
|
| Health Resources | 1 | 2010 | 950 | 0.220 |
Why?
|
| Physician's Role | 1 | 2010 | 926 | 0.210 |
Why?
|
| Public Health Informatics | 1 | 2003 | 109 | 0.210 |
Why?
|
| Intensive Care Units | 5 | 2018 | 3801 | 0.210 |
Why?
|
| Glycopeptides | 1 | 2004 | 225 | 0.200 |
Why?
|
| Fascioliasis | 1 | 2001 | 14 | 0.190 |
Why?
|
| Fasciola hepatica | 1 | 2001 | 15 | 0.190 |
Why?
|
| Hospital Information Systems | 1 | 2003 | 394 | 0.190 |
Why?
|
| Boston | 7 | 2020 | 9371 | 0.190 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 436 | 0.190 |
Why?
|
| Health Personnel | 2 | 2019 | 3380 | 0.180 |
Why?
|
| Anthelmintics | 1 | 2001 | 83 | 0.180 |
Why?
|
| Universal Precautions | 1 | 2020 | 34 | 0.180 |
Why?
|
| Local Government | 1 | 2021 | 83 | 0.180 |
Why?
|
| Mandatory Programs | 1 | 2021 | 86 | 0.170 |
Why?
|
| Caliciviridae Infections | 1 | 2020 | 29 | 0.170 |
Why?
|
| Health Facilities | 2 | 2022 | 577 | 0.170 |
Why?
|
| Methicillin Resistance | 2 | 2019 | 198 | 0.170 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2018 | 640 | 0.170 |
Why?
|
| Oseltamivir | 1 | 2019 | 75 | 0.160 |
Why?
|
| Federal Government | 1 | 2021 | 266 | 0.160 |
Why?
|
| Medication Errors | 1 | 2005 | 784 | 0.160 |
Why?
|
| Vaccination | 2 | 2021 | 3431 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 15939 | 0.150 |
Why?
|
| Soaps | 1 | 2018 | 29 | 0.150 |
Why?
|
| Masks | 1 | 2021 | 214 | 0.150 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 742 | 0.150 |
Why?
|
| Risk Factors | 12 | 2020 | 74962 | 0.150 |
Why?
|
| Drug Utilization | 3 | 2018 | 1191 | 0.150 |
Why?
|
| Daptomycin | 1 | 2018 | 71 | 0.150 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 5375 | 0.150 |
Why?
|
| o-Phthalaldehyde | 1 | 2017 | 15 | 0.150 |
Why?
|
| State Government | 1 | 2021 | 389 | 0.150 |
Why?
|
| Duodenoscopy | 1 | 2017 | 45 | 0.140 |
Why?
|
| Ethylene Oxide | 1 | 2017 | 28 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2004 | 727 | 0.140 |
Why?
|
| Humans | 51 | 2024 | 768393 | 0.140 |
Why?
|
| Sterilization | 1 | 2017 | 132 | 0.130 |
Why?
|
| Pandemics | 5 | 2024 | 8753 | 0.130 |
Why?
|
| Hospitals | 3 | 2019 | 3906 | 0.130 |
Why?
|
| Bacteremia | 3 | 2008 | 985 | 0.130 |
Why?
|
| Blood-Borne Pathogens | 2 | 2020 | 52 | 0.130 |
Why?
|
| Disinfectants | 1 | 2017 | 129 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2001 | 864 | 0.130 |
Why?
|
| Enterobacteriaceae | 2 | 2015 | 161 | 0.130 |
Why?
|
| Fosfomycin | 1 | 2015 | 25 | 0.130 |
Why?
|
| Laminectomy | 1 | 2016 | 226 | 0.130 |
Why?
|
| Anti-Infective Agents | 2 | 2018 | 985 | 0.130 |
Why?
|
| Fluoroquinolones | 2 | 2010 | 309 | 0.120 |
Why?
|
| Cystitis | 1 | 2015 | 96 | 0.120 |
Why?
|
| Travel | 1 | 2001 | 800 | 0.120 |
Why?
|
| Bacteriuria | 1 | 2015 | 102 | 0.120 |
Why?
|
| Endosonography | 1 | 2019 | 622 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 12092 | 0.120 |
Why?
|
| Enterococcus | 1 | 2015 | 159 | 0.120 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2011 | 862 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2009 | 8075 | 0.110 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 584 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 590 | 0.100 |
Why?
|
| Cohort Studies | 9 | 2013 | 41795 | 0.100 |
Why?
|
| Logistic Models | 5 | 2018 | 13323 | 0.100 |
Why?
|
| Klebsiella Infections | 2 | 2010 | 146 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 2002 | 0.090 |
Why?
|
| Infection Control Practitioners | 1 | 2010 | 12 | 0.090 |
Why?
|
| Klebsiella | 1 | 2010 | 49 | 0.090 |
Why?
|
| beta-Lactams | 2 | 2018 | 158 | 0.080 |
Why?
|
| Survivors | 1 | 2020 | 2382 | 0.080 |
Why?
|
| Bacteria | 2 | 2019 | 2221 | 0.080 |
Why?
|
| Nursing Staff, Hospital | 1 | 2013 | 350 | 0.080 |
Why?
|
| Hospital Departments | 1 | 2010 | 135 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2015 | 959 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2018 | 22296 | 0.080 |
Why?
|
| Indinavir | 1 | 1998 | 73 | 0.080 |
Why?
|
| Psychiatry | 1 | 2021 | 1715 | 0.080 |
Why?
|
| Adult | 12 | 2020 | 223640 | 0.080 |
Why?
|
| Female | 22 | 2020 | 397089 | 0.080 |
Why?
|
| Health Services | 1 | 2013 | 756 | 0.080 |
Why?
|
| Electronic Mail | 1 | 2010 | 215 | 0.080 |
Why?
|
| Perineum | 1 | 2009 | 211 | 0.070 |
Why?
|
| Male | 21 | 2020 | 364902 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 1276 | 0.070 |
Why?
|
| HIV Infections | 3 | 2009 | 17575 | 0.070 |
Why?
|
| Cities | 1 | 2010 | 543 | 0.070 |
Why?
|
| Nasal Cavity | 1 | 2009 | 311 | 0.070 |
Why?
|
| Spinal Fusion | 1 | 2016 | 1309 | 0.070 |
Why?
|
| United States | 11 | 2024 | 73150 | 0.070 |
Why?
|
| Workload | 1 | 2013 | 852 | 0.070 |
Why?
|
| Hospitals, Urban | 2 | 2011 | 500 | 0.070 |
Why?
|
| Aged | 11 | 2020 | 171562 | 0.070 |
Why?
|
| Outpatients | 2 | 2018 | 1604 | 0.070 |
Why?
|
| HIV Protease Inhibitors | 1 | 1998 | 432 | 0.070 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 2005 | 55 | 0.070 |
Why?
|
| Middle Aged | 11 | 2020 | 223491 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 9682 | 0.060 |
Why?
|
| Sentinel Surveillance | 2 | 2007 | 292 | 0.060 |
Why?
|
| Respiration, Artificial | 2 | 2015 | 2721 | 0.060 |
Why?
|
| Forms and Records Control | 1 | 2005 | 158 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 1998 | 469 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 5538 | 0.060 |
Why?
|
| Hospital Administration | 1 | 2007 | 353 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1813 | 0.060 |
Why?
|
| Young Adult | 3 | 2017 | 60049 | 0.050 |
Why?
|
| HIV-2 | 1 | 2004 | 156 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2009 | 1026 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2019 | 81801 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2013 | 1959 | 0.050 |
Why?
|
| Patient Care | 1 | 2009 | 629 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 59686 | 0.050 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 166 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 941 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2022 | 43 | 0.050 |
Why?
|
| Breast | 1 | 2011 | 1975 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2004 | 253 | 0.050 |
Why?
|
| Decontamination | 1 | 2022 | 73 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5713 | 0.050 |
Why?
|
| Antibodies, Helminth | 1 | 2001 | 58 | 0.050 |
Why?
|
| Africa, Western | 1 | 2001 | 160 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2009 | 1345 | 0.050 |
Why?
|
| Health Maintenance Organizations | 1 | 2003 | 658 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3324 | 0.040 |
Why?
|
| Pregnancy | 2 | 2013 | 30200 | 0.040 |
Why?
|
| Contact Tracing | 1 | 2022 | 275 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2013 | 3267 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2019 | 54920 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 14154 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 1158 | 0.040 |
Why?
|
| Sulbactam | 1 | 2018 | 32 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2008 | 1177 | 0.040 |
Why?
|
| Ampicillin | 1 | 2018 | 137 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2015 | 1961 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 397 | 0.040 |
Why?
|
| Cefazolin | 1 | 2018 | 95 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2015 | 1063 | 0.040 |
Why?
|
| Metronidazole | 1 | 2018 | 233 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2011 | 26411 | 0.030 |
Why?
|
| Gases | 1 | 2017 | 204 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2017 | 328 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2005 | 1876 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 277 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 611 | 0.030 |
Why?
|
| Nitrofurantoin | 1 | 2015 | 18 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2005 | 1222 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7453 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2020 | 708 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 1133 | 0.030 |
Why?
|
| Employment | 1 | 2021 | 1116 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 1561 | 0.030 |
Why?
|
| Feces | 1 | 2001 | 1512 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 520 | 0.030 |
Why?
|
| Sepsis | 1 | 2008 | 2601 | 0.030 |
Why?
|
| Time Factors | 4 | 2017 | 40272 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2015 | 313 | 0.030 |
Why?
|
| Pneumonia | 1 | 2005 | 2163 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 509 | 0.030 |
Why?
|
| Judgment | 1 | 2015 | 272 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2020 | 1084 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 1998 | 4571 | 0.030 |
Why?
|
| Incidence | 4 | 2014 | 21544 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 14737 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2011 | 6241 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2018 | 2079 | 0.020 |
Why?
|
| Forecasting | 1 | 2021 | 2948 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2004 | 4211 | 0.020 |
Why?
|
| Markov Chains | 1 | 2015 | 977 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 2412 | 0.020 |
Why?
|
| Models, Economic | 1 | 2015 | 718 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 6085 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 1045 | 0.020 |
Why?
|
| Policy Making | 1 | 2014 | 545 | 0.020 |
Why?
|
| Length of Stay | 2 | 2015 | 6519 | 0.020 |
Why?
|
| beta-Lactam Resistance | 1 | 2010 | 79 | 0.020 |
Why?
|
| Pediatrics | 1 | 2005 | 3624 | 0.020 |
Why?
|
| Massachusetts | 1 | 2022 | 8902 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2570 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2015 | 1162 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 89184 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 8051 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2010 | 307 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 2623 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3438 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2016 | 24318 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 1359 | 0.020 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2000 | 408 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2011 | 562 | 0.020 |
Why?
|
| Health Care Sector | 1 | 2007 | 197 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 2437 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 7955 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 4047 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 1142 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 20224 | 0.020 |
Why?
|
| Hemophilia A | 1 | 1998 | 359 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2007 | 210 | 0.020 |
Why?
|
| Child | 2 | 2021 | 80891 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 142 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8562 | 0.010 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 125 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10588 | 0.010 |
Why?
|
| Health Policy | 1 | 2014 | 2698 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18362 | 0.010 |
Why?
|
| ROC Curve | 1 | 2008 | 3623 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 2004 | 524 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6318 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 4056 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 169337 | 0.010 |
Why?
|
| Hepatitis C | 1 | 1998 | 1593 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 2596 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2013 | 4848 | 0.010 |
Why?
|
| Hospitalization | 2 | 2010 | 10844 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 1903 | 0.010 |
Why?
|
| Survival Rate | 1 | 2000 | 12870 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2000 | 12558 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 3398 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 26375 | 0.010 |
Why?
|